Diabetes patients on insulin, suffering from acute injection phobia, have an alternative with the launch of Oral-Recosulin , arecombinant DNA human insulin buccal spray.
The spray, which is on phase-3 trial and yet to be launched in the US, has been approved for marketing in India.

Announcing the launch, Shreya Life Science Pvt Ltd, domestic business director Ram Shelat said: "It has been approved for marketing in India. We are waiting for price approval, and by the first week of December, it will be available in the Indian market."

For the treatment of both Type-1 and Type-2 diabetes, Oral-Recosulin can be used. This buccal insulin spray is developed by Shreya Life Science Pvt Ltd's US collaborator Generex Biotechnology.

Buccal spray delivers insulin through buccal mucosa, directly to the vascular system without entering the lungs."Approximately, it costs Rs 2,000 per pack and each pack offers 80 units.

Tag :nasal insulin spray,insulin spray generex,diabetes insulin spray,insulin sprays,insulin spray injector,diabetic insulin spray,oralin insulin spray,pfizer insulin spray,new insulin spray,insulin spray for diabetes